Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study

被引：0
|
作者：
Estévez, LG
Adrover, E
Barnadas, A
Cuevas, JM
Seguí, MA
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [21] Which is your choice? Neoadjuvant doxorubicin hydrochloride and doxetaxel (AD) versus doxorubicin hydrochloride, cyclophosphamide, and paclitaxel (AC-T) in locally advanced breast cancer
    Kang, Seok Yun
    Choi, Jin-Hyuk
    Kim, Ku Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
    L. G. Estévez
    P. Sánchez-Rovira
    M. Dómine
    A. León
    I. Calvo
    A. Jaén
    V. Casado
    G. Rubio
    M. Díaz
    C. Miró
    F. Lobo
    E. Carrasco
    M. Casillas
    B. San Antonio
    Clinical and Translational Oncology, 2007, 9 : 317 - 322
  • [23] Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
    Kim, Se Hyun
    Jung, Kyung Hae
    Kim, Tae-Yong
    Im, Seock-Ah
    Choi, In Sil
    Chae, Yee Soo
    Baek, Sun Kyung
    Kang, Seok Yun
    Park, Sarah
    Park, In Hae
    Lee, Keun Seok
    Choi, Yoon Ji
    Lee, Soohyeon
    Sohn, Joo Hyuk
    Park, Yeon-Hee
    Im, Young-Hyuck
    Ahn, Jin-Hee
    Kim, Sung-Bae
    Kim, Jee Hyun
    CANCER RESEARCH AND TREATMENT, 2016, 48 (04): : 1373 - 1381
  • [24] Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Rolski, J.
    Chan, A.
    Mackey, J.
    Liu, M.
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T.
    Olsen, S.
    Buyse, M.
    Kiskartalyi, T.
    Landreau, V
    Wilson, V
    Press, M.
    Crown, J.
    CANCER RESEARCH, 2009, 69 (24) : 500S - 500S
  • [25] Primary prophylaxis with 3 weekly Darbepoetin alfa effectively prevents anaemia during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients
    Von Minckwitz, G
    Loibl, S
    Petrich, S
    Kimarasamy, V
    Hoffmann, K
    Schickling, O
    Kaufmann, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S231 - S231
  • [26] Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
    Zhang, Minmin
    Wei, Wei
    Liu, Jianlun
    Yang, Huawei
    Jiang, Yi
    Tang, Wei
    Li, Qiuyun
    Liao, Xiaoming
    ONCOTARGETS AND THERAPY, 2016, 9 : 3443 - 3450
  • [27] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    Buzdar, AU
    Singletary, SE
    Theriault, RL
    Booser, DJ
    Valero, V
    Ibrahim, N
    Smith, TL
    Asmar, L
    Frye, D
    Manuel, N
    Kau, SW
    McNeese, M
    Strom, E
    Hunt, K
    Ames, F
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3412 - 3417
  • [28] Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer
    Tuxen, Malgorzata K.
    Cold, Soeren
    Tange, Ulla B.
    Balslev, Eva
    Nielsen, Dorte L.
    ACTA ONCOLOGICA, 2014, 53 (10) : 1440 - 1445
  • [29] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [30] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
12345